Publix Purified Water Vs Distilled, Beaverhead County Coroner, Where To Donate Fine China And Crystal, Cva Paramount Trigger Adjustment, Vikings Seer Prophecy Ragnar Sons, Articles O

Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Typically, I care little about financials with biotechs. Please check your download folder. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Ocugen isnt a promotional, fly-by-night penny stock. If they invent a miracle treatment for a condition, the money will find its way to the stock. But if they do, Ocugen stock at the least looks like an intriguing bet. 1125 N. Charles St, Baltimore, MD 21201. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. How can we possibly evaluate a stock on a fundamental basis with that being reality? Thats why we give you a wide range of Options on stocks, indices, commodities and FX. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). Is Ocugen Stock Still Worth Buying After Its 800%-Plus Rally? Analyst Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Ill be sticking to the stocks that are actually working. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. OCGN does not even appear to have an apparent reason to exist. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. In this case, shares rallied about four-fold in just a few days. quotes delayed at least 15 minutes, all others at least 20 minutes. Nasdaq It has no treatments to offer the market. Ocugen Inc. is a clinical stage biopharmaceutical company. 1125 N. Charles St, Baltimore, MD 21201. The second is that the balance sheet still needs some help. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Ocugen Inc. Announces Closing of $100 Million Registered But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. At the beginning of 2020, Ocugen shares were trading at just 47 cents. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Create your Watchlist to save your favorite quotes on Nasdaq.com. Keith Speights owns shares of Pfizer. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? Can you feel the ground moving beneath your feet? So far, that merger hasnt worked out for Histogenics former shareholders. Create your Watchlist to save your favorite quotes on Nasdaq.com. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. All rights reserved. Long-term debt of $1.6 million is not a back-breaker either. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Keith Speights has no position in any of the stocks mentioned. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). Investors were hopeful that the small drugmaker would be able to win U.S. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. The Motley Fool->. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. *Average returns of all recommendations since inception. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. You canfollow Will on Twitterat @HealyWriting. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. Investors need to understand the risk profile here. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. OCGN | Ocugen Inc. Stock Price & News - WSJ Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. But the allure of the space is that when a company wins, its shareholders win big. Start trading Options with Saxo today. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. Literally, zero. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Click here to see what Matt has up his sleeve now. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. market." Its worth emphasizing: Ocugen stock is a play with enormous risk. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. What Is the Best EV Stock to Buy Now? David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. You never know when they will suddenly go on a squeeze. The biotech stock promptly crashed by more than 30%. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. For priority reviews, the timeline for an approval decision is reduced to six months. Lorem ipsum dolor sit amet, consectetur adipiscing elit. If you missed that action, you missed all the gains. Why Ocugen Stock Is Crashing Today | The Motley Fool - Nasdaq That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Type a symbol or company name. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. The short answer is: everything. It is very important to do your own analysis before making any investment. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. All rights reserved. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Ocugen: Peripheral Scandals Taint This Expired COVID-19 'Me-Too' Longshot 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. The FDA's decision not to issue EUA really wasn't all that surprising, though. That's not going to happen now. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." But realizing value in practice usually is a difficult endeavor. Copyright 2023 InvestorPlace Media, LLC. Please check your download folder. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Maybe OCGN stock will be one of them again. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Learn More. Most biotech companies have intriguing stories on paper; Ocugen is no different. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. OCGN - Ocugen Inc Forecast - CNNMoney.com - CNN Business Ocugen Stock Crashes: What Should Investors Do Now? First, the balance sheet is in at least decent shape. Type a symbol or company name. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Here are three prudent steps to take. It's hard to say for sure. The average Ocugen stock price for the last 52 weeks is 2.10. The stock had gained some traction after they announced the. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. Instead, this appears destined to join the long list of failed biotech startups. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. Its certainly possible. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. However, sometimes the optimism isn't justified. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. The potential synergies of such a union do not seem clear. If OCU300 is approved, theres a reasonably large market. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Companies will inevitably be optimistic about their prospects for success (at least publicly). Even before that point, the most promising candidates generally can find funding. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. This can prove to be a costly lesson to learn. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. 1125 N. Charles St, Baltimore, MD 21201. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. If Ocugen goes up, you can still profit. If You Invested $1,000 In Ocugen Stock One Year Ago, Here's - Insider And its at least possible that OCGN could wind up being a winner. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. 2023 InvestorPlace Media, LLC. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Accordingly, the analyst rates OCGN a Neutral (i.e. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. Theres even room for more lines. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. To be sure, current cash isnt enough. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. The $25 million private placement executed before the merger brought in much-needed cash. These symbols will be available throughout the site during your session. OCGN Stock Price | Ocugen Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. That product drives the current bull case for Ocugen stock. Those lessons will vary between different investors, but I'll point out a major one to keep in mind. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. This requires no immediate effort on your part. Type a symbol or company name. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Investors should worry about companies with no revenue even under the best of circumstances. Ocugen to Present at the 2018 BIO International Convention | Ocugen, Inc. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. Why Ocugen Stock Is Crushing It Today | Nasdaq While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. These symbols will be available throughout the site during your session. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Our 3 Top Picks. Written by If they have solid financials, but their trials continually fail, they will likely not succeed. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. *Stock Advisor returns as of November 20, 2020. Bharat Biotech has a history of successful vaccine commercialization in South Asia. Investors who have owned stocks in the last year have generally experienced some big gains. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. 2023 InvestorPlace Media, LLC. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. At the time, Ocugen was left for dead. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Ocugen. Copy and paste multiple symbols separated by spaces. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. *Stock Advisor returns as of June 7, 2021. So, what goes wrong? As of this writing, Matt did not hold a position in any of theaforementioned securities. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Copyright Theres an opportunity here. Why Ocugen Stock Dropped Today | The Motley Fool - Nasdaq Nasdaq As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. The chances of anything more are small but the rewards could be huge. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Like other life sciences companies involved in Covid-19 vaccine. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. Thats the thing with these low-priced penny stocks. That's right -- they think these 10 stocks are even better buys. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Its all about choice. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. Ocugen had to go an unusual route to go public. It has real management. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents.